An Sp1/Sp3 binding polymorphism confers methylation protection. by Boumber, Yanis A et al.
An Sp1/Sp3 Binding Polymorphism Confers Methylation
Protection
Yanis A. Boumber1,2, Yutaka Kondo1¤a, Xuqi Chen1¤b, Lanlan Shen1, Yi Guo1, Carmen Tellez1, Marcos R. H.
Este´cio1, Saira Ahmed1, Jean-Pierre J. Issa1,2*
1Department of Leukemia, M. D. Anderson Cancer Center, University of Texas, Houston, Texas, United States of America, 2 Program in Cancer Biology, Graduate School of
Biomedical Sciences, University of Texas, Houston, Texas, United States of America
Abstract
Hundreds of genes show aberrant DNA hypermethylation in cancer, yet little is known about the causes of this
hypermethylation. We identified RIL as a frequent methylation target in cancer. In search for factors that influence RIL
hypermethylation, we found a 12-bp polymorphic sequence around its transcription start site that creates a long allele.
Pyrosequencing of homozygous tumors revealed a 2.1-fold higher methylation for the short alleles (P,0.001). Bisulfite
sequencing of cancers heterozygous for RIL showed that the short alleles are 3.1-fold more methylated than the long
(P,0.001). The comparison of expression levels between unmethylated long and short EBV-transformed cell lines showed
no difference in expression in vivo. Electrophorectic mobility shift assay showed that the inserted region of the long allele
binds Sp1 and Sp3 transcription factors, a binding that is absent in the short allele. Transient transfection of RIL allele-
specific transgenes showed no effects of the additional Sp1 site on transcription early on. However, stable transfection of
methylation-seeded constructs showed gradually decreasing transcription levels from the short allele with eventual
spreading of de novo methylation. In contrast, the long allele showed stable levels of expression over time as measured by
luciferase and ,2–3-fold lower levels of methylation by bisulfite sequencing (P,0.001), suggesting that the polymorphic
Sp1 site protects against time-dependent silencing. Our finding demonstrates that, in some genes, hypermethylation in
cancer is dictated by protein-DNA interactions at the promoters and provides a novel mechanism by which genetic
polymorphisms can influence an epigenetic state.
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Introduction
Causes of promoter DNA hypermethylation in cancer are
unknown. Possibilities range from random events selected for to a
model whereby an initial drop of transcription rate allows
elimination of active chromatin boundaries and spreading of DNA
methylation from ‘‘DNA methylation centers’’- perhaps, repeat
elements [1]. Alternatively, aberrant methylation might be caused by
a repressor binding to the promoter and altering chromatin state to a
closed configuration, which eventually causes abnormal methylation
via recruitment of DNA methyltransferase [2,3]. Furthermore,
methylation seeding and ongoing transcription as well as possibly
transcription factor binding seem to be required for the protection of
promoters against methylation [4]. Nevertheless, the details and
order of events in these processes remain elusive.
RIL is a ubiquitously expressed gene, which was originally
identified as a candidate tumor suppressor [5]. Human RIL maps to
chromosome 5q31.1, a region frequently deleted in the malignant
cells of patients with myelodysplastic syndrome (MDS) and acute
myelogenous leukemia (AML) [6], and appears to be a good
candidate for one of the tumor-suppressor genes that reside in this
area. Using methylated CpG island amplification [7] in the K562
cell line, we identified RIL as a novel gene aberrantly methylated in
cancer. RIL CpG island is unmethylated in normal tissues, and is
one of the most frequent targets for hypermethylation in various
cancer cell lines and primary tumors. Hypermethylation of RIL
correlates with loss of gene expression, which could be restored in
methylated cell lines by 5-aza-dC. Moreover, RIL reexpression leads
to a suppression of tumor cell growth and clonogenicity in soft agar
as well as sensitization of cells to apoptosis [8].
Here, we describe a polymorphism in the RIL promoter that
creates an Sp1/Sp3 binding site and protects against methylation
in cancer.
Results
In search for causes of aberrant hypermethylation of RIL in
cancer, a ,500-bp region around the transcription start site of the
RIL promoter was sequenced, and a previously unknown
polymorphic insertion was identified in the gene. In the
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population, 2 alleles of RIL exist, long and short, with a
polymorphic area near a CGG repeat sequence adjacent to the
transcription start site. The long allele is created by insertion of a
12-bp fragment (CGGCGGCGGCTC) and a substitution of T to
G 3 bases upstream of the insertion site in the short allele
(Figure 1A). In silico analysis identified additional putative binding
sites for 3 transcription factors which appear only in the long allele.
To more fully characterize this phenomenon and determine the
frequency of alleles, a total of 326 normal samples were sequenced,
which included 227 normal colon and 99 normal blood samples.
In the normal population, 45% of people are homozygous for the
short allele, 44% heterozygous and 11% homozygous for the long
RIL allele. We have also determined the frequency of the RIL
alleles among 240 cancer specimen which included 113 colon
cancers, 100 MDS and 27 AML samples. We found that 44% of
those were homozygous for the short allele, 40% heterozygous and
16% homozygous for the long RIL allele.
Differential methylation of the two RIL alleles was initially
discovered after development of a COBRA assay. We initially
noticed that methylated heterozygous tumors analyzed by
COBRA seem to have preferential methylation of the short allele.
After digestion of the COBRA products obtained from several
homozygous and heterozygous tumors, we observed that among
the 2 allele-specific bands, the predominant one is the lower band,
which represents methylated short allele molecules (Figure S1).
This led us to a suspicion that the short allele is more methylated
than the long. For further studies, we decided to use pyrosequen-
cing method, which is more quantitative in detecting methylation.
To make sure that no amplification bias exists in detecting
methylation, we designed all the assays primers either upstream or
downstream of the insertion. We then tested the pyrosequencing
assay A (Figure 1A) by studying mixed normal unmethylated with
methylated DNA at known ratios, and found no bias in amplifying
unmethylated vs. methylated DNA (Figure S2). Next, we studied
methylation in 48 primary cancer samples (18 homozygous long
and 30 homozygous short) which included 44 colon cancer and 4
AML cases with this assay, and found that homozygous short
tumors showed mean 51.7%+/23.8% methylation density vs.
mean 24.7%+/24.5% methylation for homozygous RIL long
tumors, and thus had a 2.1 fold increased methylation density
(P,0.001) (Figure 1B). We also studied 34 MDS samples (which
included 11 homozygous long and 23 homozygous short) using
pyrosequencing assay B (see Figure 1B) and found similar results:
homozygous short RIL samples showed mean 35.5%+/25.4%
methylation density vs. mean 14.7%+/22.4% methylation for
homozygous RIL long samples, P= 0.001) (a 2.4 fold difference).
To confirm the latter observations, we performed bisulfite
sequencing of 10 methylated tumors with heterozygous alleles (6
colon cancer and 4 AML). These data showed that in 8 out of 10
samples studied, the short allele is the primary methylation target,
whereas the long one is largely unmethylated (Figure 1C). In the
case of AML7, both alleles were methylated, and in case C113
there was a mixture of unmethylated and methylated alleles with
no difference in methylation. Furthermore, in C140 and AML5
many of the S alleles remain unmethylated; however this finding
may well represent contamination from normal tissues in which
both L and S alleles are largely unmethylated, or co-existence of
unmethylated and methylated tumor cells. However, even in
samples C140 and AML5, the number of methylated clones is
higher for the S allele. Using methylation of .30% of CpG sites
within the clone as an arbitrarily chosen cutoff for dense
methylation, the short alleles were 3.1 times more methylated
than the long alleles (p,0.001 by the Fisher exact test).
Quantitatively similar results are obtained if the cutoff is 20%,
50%, or without using any cutoff (not shown). Taken together,
these data demonstrate unequivocally preferential methylation of
the short alleles even when they coexist with the long alleles within
the same tumor.
We previously found that RIL methylation increases with age in
normal colon [8]. To investigate whether this is influenced by the
polymorphism, we studied 46 normal colon samples (17
homozygous short, 15 heterozygous and 14 homozygous long,
obtained from individuals with comparable age) using 5
pyrosequencing methylation assays, each covering several CpG
sites around the transcription start site, as well as exon 1 and
intron 1 regions (Figure 1A, Table S1). We found that
homozygous long samples were significantly less methylated
compared to homozygous short in all the regions studied, both
upstream and downstream of transcription start site (Figure 1D).
Average methylation percent for the upstream region measured by
assays A–F was 34.361.8 for homozygous short cases, 26.862.2
for heterozygous, and 19.461.1 for homozygous long cases and
therefore the short alleles were 1.8 times more methylated in the
normal colon. Finally, all samples showed increased methylation
with age, independent of allele status (R=0.42, p = 0.09 for
homozygous short, R= 0.57, p = 0.03 for heterozygous, R=0.69,
p = 0.01 for homozygous long cases (Figure 1D).
We were puzzled by the finding of differential allele methylation
and thought that one likely explanation for such a difference is
lower expression of the short alleles predisposing them to
methylation. We therefore investigated whether the expression
levels between the alleles are different in vivo. First, we obtained
and genotyped 96 primary EBV-transformed lymphoblastoid cell
lines established from normal individuals and found that 42 of
those were homozygous short, 42 heterozygous, and 12 homozy-
gous long. We then analyzed 24 cell lines (12 long and 12 short)
for methylation status of RIL by pyrosequencing. We found
variable levels of methylation among the cell lines, which was
higher for short cell lines, although the difference was not
statistically significant (Figure 2A). Nevertheless, this difference
Author Summary
The factors that guide DNA hypermethylation in cancer are
poorly understood. We identified the candidate tumor-
suppressor gene, RIL, as a frequent methylation target in
cancer. Here, we report on a 12-bp polymorphic sequence
around its transcription start site that creates a long allele.
Methylation analysis showed that, in aging colon, colon
cancer, and leukemias, the short allele had 2.1–3.1-fold
higher methylation than the long allele (P,0.001). Short
and long alleles had similar expression levels in EBV-
transformed cell lines. Electrophorectic mobility shift assay
showed that the inserted region of the long allele binds
Sp1 and Sp3 transcription factors. Transfection of RIL
allele-specific transgenes showed no effects of the
additional Sp1 site on transcription early on, but methyl-
ation-seeded constructs showed gradually decreasing
transcription from the short allele with eventual spreading
of de novo methylation. By contrast, the long allele showed
stable expression over time as measured by luciferase, and
,2–3-fold lower levels of methylation by bisulfite
sequencing (P,0.001), suggesting that the polymorphic
Sp1 site protects against time-dependent silencing. Our
finding demonstrates that in some genes, hypermethyla-
tion in cancer is dictated by protein-DNA interactions at
the promoters and provides a novel mechanism by which
genetic polymorphisms can influence an epigenetic state.
Sp1/Sp3 Confer Methylation Protection
PLoS Genetics | www.plosgenetics.org 2 August 2008 | Volume 4 | Issue 8 | e1000162
Sp1/Sp3 Confer Methylation Protection
PLoS Genetics | www.plosgenetics.org 3 August 2008 | Volume 4 | Issue 8 | e1000162
was quantitatively similar to what we saw in normal (non-
malignant) colon tissues. We studied RIL expression in these
samples by quantitative PCR and found it to correlate well with
methylation (Figure 2B). We then excluded 11 cell lines with
methylation above 15% and compared 8 unmethylated homozy-
gous long with 5 unmethylated homozygous short cell lines and
found no difference in expression (Figure 2C). This led us to
conclude that there is no difference in expression between the long
and short alleles in a physiologic setting.
We next hypothesized that the insertion polymorphism creates
binding sites for a protein that protects the long allele against
methylation. To determine whether nuclear proteins can bind to
the polymorphic region of the long or short alleles, we first
performed electrophoretic mobility shift assays (EMSA) with
nuclear extracts from different cell lines using double-stranded
radiolabeled oligonucleotides that corresponded to bp269 to237
(L) or 257 to 237 (S) relative to the translation start site (see
Figure 3A) of the long and short RIL alleles, respectively. We found
strong DNA-binding activity for the L probe in 3/4 cell lines tested
(PC3, MDA-MB-231, OVCAR5), whereas no detectable DNA
binding activity was observed with the S probe using the same
nuclear extracts, even at longer exposures (Figure 3B). Three major
shifted bands were found as a result of this L probe DNA-binding
activity. Specificity of those bands was confirmed by competition
with unlabeled oligonucleotides (not shown). To map the region
responsible for binding, we synthesized shorter versions of the L
probe of an equal size to the original S probe: L1, corresponding to
nucleotides 269 to 249; L2, nucleotides 257 to 237; and L3,
nucleotides 263 to 243 (Figure 3A). EMSA results with the
nuclear extracts from MDA-MB-231 cells indicated that, while
probe L2 had a strong DNA-binding activity resulting in
appearance of 3 distinct bands, probes L1 and L3 had no
detectable DNA-binding activity (Figure 3C, first three lanes).
To identify the nature of proteins bound to the long allele, we
performed supershift assays using different antibodies. When the
L2 probe was mixed with nuclear extracts from MDA-MB-231,
and then incubated with an anti-Sp1 antibody, the top band was
diminished, and supershifted complexes were formed, indicating
that the top band contained Sp1 (Figure 3C). Incubation of the L2
probe with the nuclear extracts in the presence of Sp3 antibody
Figure 2. Allele-Specific Expression of RIL in Homozygous EBV-Transformed Cell Lines. (A) Left, Graphic representation of RIL methylation
as determined by pyrosequencing with assay A in 12 long (L) and 12 short (S) EBV-transformed cell lines is shown (values represent averages of two
independent pyro measurements for each sample). Right, average methylation values+/2SEM for homozygous long and homozygous short sample
groups are shown. (B) Graphic representation of correlation between relative expression by quantitative PCR (RIL/GAPDH) and methylation for each
EBV sample studied is shown. (C) Average expression values+/2SEM for unmethylated homozygous long (N= 8) and homozygous short (N = 5) cell
lines with methylation below 15% are shown.
doi:10.1371/journal.pgen.1000162.g002
Figure 1. Identification of RIL Promoter Polymorphism and Preferential Methylation of the Short Allele in Cancer. (A) Map of RIL the
CpG island. The distribution of CpG sites is represented by vertical bars. The transcription start site is indicated by an arrow. Letters A to G, location of
pyrosequencing assays. Asterisk above the CpG map indicates the location of the COBRA assay. RIL exon 1 is shown as a box below the CpG island.
The inserted 12-bp region in the long allele within the untranslated region of exon1 is shown in a grey box, with the upstream t is changed to g (t
marked with an asterisk). Two previously described transcription start sites are underlined. (B) RIL shows lower methylation in homozygous long
samples. Left, graphic representation of average RIL methylation values+/2SEM determined by pyrosequencing with assay A in 18 long (L/L) and 30
short (S/S) primary colon and AML samples are shown. Right, graphic representation of average RIL methylation values+/2SEM determined by
pyrosequencing with assay B in 11 long (L/L) and 23 short (S/S) primary MDS samples are shown. (C) Heterozygous cases (L/S) have preferential
methylation of RIL short allele. Bisulfite sequencing results are shown for the heterozygous colon tumors C110, C125, C128 and C140, C106, C112,
C113; and heterozygous AML cases AML4, AML5, AML7 (right). Open and closed circles represent unmethylated and methylated CpG dinucleotides,
respectively. Each line of circles represents a single cloned allele. The deletion region is shown by a dashed line. The proximal transcription start site is
indicated by an arrow. Overall, there is a 3.1-fold difference (P,0.001) in the methylation status of RIL long and short alleles (especially obvious in
C110, C125, C128; AML4, AML5). (D) left, average methylation values+/2SEM of 17 homozygous short (black line) and 14 homozygous long (grey
dashed line) normal colon samples measured using pyrosequencing assays A to G; right, correlation between average methylation values and age for
the assays A to F among 17 short (black diamonds) and 14 long (grey circles) normal colon samples.
doi:10.1371/journal.pgen.1000162.g001
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completely abolished the two lower bands and resulted in
supershifted bands (Figure 3C). Incubation of the L probe with
the nuclear extracts and both Sp1, Sp3 antibodies resulted in
almost complete disappearance of all three bands, whereas an Egr-
1 antibody had no effect on the shifts. We confirmed these results
using recombinant human Sp1 (data not shown).
The results of EMSAs strongly suggested that binding of Sp1
and Sp3 proteins occurs in the 3CTC-containing region of the
inserted region of the long allele. First, the L1 and L3 probes were
unable to show any DNA-binding activity, and both do not have
an intact 3CTC region. Second, the S probe which was also not
bound by factors in the nuclear extracts, contains a 2CTC repeat,
and in fact has only a 2-nucleotide difference with the L2 probe,
thus being a naturally occurring mutant of L2 (Figure 3A). Finally,
the 3CTC sequence has been previously shown to be a variant Sp1
site, important for regulation of several genes, including WT1 [9].
To map Sp1/Sp3 binding in this region, we generated a series of
oligonucleotides with 3-bp mutations throughout the probe (LM1-
LM6); and oligonucleotides with 2-bp mutations restricted to the
3CTC region (LM7-LM10) (see Figure 3A). We then competed the
L2 probe with a 20-fold excess of various unlabeled competitors.
These experiments revealed poor competition capacity of all the
probes where the 3CTC repeat is absent (S, Egr1, LM3-LM5, LM7-
LM10 probes), and efficient competition by all probes containing an
intact 3CTC sequence (Figure 3D). Identical results were obtained in
OVCAR-5 cells (data not shown).
Next, we sought to determine whether the additional Sp1/Sp3
binding site in the long allele affects transcription in vitro. We
generated three different luciferase constructs driven by allele-
specific RIL promoter fragments containing the polymorphic
region of2588 to +19 (A),2217 to +19 (B) and2588 to +516 (C).
In a series of transient transfections using 4 cell lines for constructs
A and B and 2 cell lines for construct C, no significant differences
in luciferase activity between the allele-specific constructs were
observed (Figure 4A), suggesting that the additional Sp1 site had
no substantial effect on RIL transcription. This was consistent with
the earlier experiments in lymphocytes.
To determine whether the additional Sp1/Sp3 binding site
confers protection against DNA methylation in vitro, we used the
same constructs described earlier. We initially stably co-transfected
unmethylated RIL allele-specific constructs (construct B) with
neomycin-containing plasmids into the mammalian cell lines
RKO and NIH3T3, and found that those maintained expression
over 3 months, and were resistant to de novo methylation (data not
shown), as previously reported for multiple genes [4]. Further-
more, it has been previously shown using GSTP1 gene as a model
that aberrant methylation at a given promoter requires pre-
existing ‘‘seeds’’ of methylation which trigger silencing [4]. To
trigger silencing in our system, we used methylation ‘‘seeding’’ of
allele-specific transgenes using HpaII methylase, which methylates
9.3% of the total CpG sites in construct B (13.5% of CpGs of the
RIL promoter fragment), and co-transfected those with neomycin-
containing plasmids into NIH3T3 cells. The plasmid methylation
status prior to transfection was validated by HpaII methylation
sensitive restriction enzyme digestion (Figure S3). After neomycin
selection, pooled clones were passaged and analyzed for luciferase
expression and methylation. We chose to use pooled clones to
avoid the problem of insertion site variegation effect of single
Figure 3. Identification of an Additional Sp1/Sp3 Binding Site in the Long Allele of RIL. (A) Sequences of EMSA probes. L probe sequence
is shown on top. The 12-bp region absent in the short allele is shown in a grey box, and T, converted to G in the short allele, is shown in bold. Putative
transcription factor binding sites (Transfac/MatInspector prediction) are shown. Mutations are shown in bold (probes LM1-LM10). Bolded nucleotides
in the S probe correspond to the nucleotides different with the long probe. The CTCCTCCTC sequence is underlined. The ability of the probes to
compete with the L2 probe is indicated on the right (+ or 2). (B) Nuclear extracts from various cancer cells were incubated with the 33-bp L or 21-bp
S probe. Note the presence of shifts with the L, but not with the S probe, which are indicated by arrows. (C) Nuclear extracts from MDA-MB-231 cells
were incubated with three shorter 21-bp versions of the L probe (L1-L3). Notice binding only with the L2 probe, which has an intact 3CTC region. To
identify the nature of proteins bound, supershift assays (arrows) of the L2 probe with specific antibodies for Sp1, Sp3, and Egr-1 were performed with
MDA-MB-231 nuclear extract. (D) To confirm binding specificity of the L2 probe and to map the nucleotides involved in binding, competition
experiments against the L2 probe were performed with 206 excess of unlabeled oligonucleotides using MDA-MB-231 cell line nuclear extract.
doi:10.1371/journal.pgen.1000162.g003
Sp1/Sp3 Confer Methylation Protection
PLoS Genetics | www.plosgenetics.org 5 August 2008 | Volume 4 | Issue 8 | e1000162
Figure 4. Induction of Hypermethylation and Silencing of the RIL Short Allele in Vitro. (A) Summary of transient allele-specific RIL/reporter
gene expression in 4 cell lines. ,0.2 KB (A), ,0.6 KB (B) and ,1.1 KB (C) RIL L and S promoter fragments were cloned upstream of pGL3 luciferase
and transiently cotransfected with renilla thymidine kinase as a transfection control into the indicated cell lines in 6-well plates. Cells were harvested
at 48 hrs and luciferase activities were analyzed. Luciferase/renilla ratios were plotted on the Y-axis. Transfections were performed in triplicates, and
standard error bars for each experiment are shown on the graph. (B) Expression of stably transfected HpaII-seeded constructs. Long and short RIL
allele-specific constructs (construct B, ,0.6 KB) were seeded with HpaII methylase, stably cotransfected with pcDNA3.1 into NIH3T3 cells, selected in
neomycin and pooled clones monitored for the indicated time period. Notice initial equal levels of expression, followed by maintenance of the long
allele construct expression and rapid decline in expression of the short allele construct. (C) Bisulfite sequencing results for allele-specific seeded
constructs. The methylation status of the transfected allele-specific constructs was analyzed by bisulfite sequencing at indicated time points, using
Sp1/Sp3 Confer Methylation Protection
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clones. Moreover, such a strategy is commonly accepted and has
been successfully used before in a similar study [10]. We measured
copy number for every time point and adjusted expression levels of
each construct accordingly. As shown in Figure 4B, luciferase
readings for both plasmids increased initially, concomitant with
stable integration and neomycin selection. However, beyond day
36 post-transfection, RIL expression seemed to be stable for long
alleles throughout the course of the experiment, but showed rapid
declines for the short alleles. A completely independent seeding/
transfection experiment with the same cell line showed similar
results (Figure S4). We then analyzed methylation status of the
constructs after stable transfection with bisulfite sequencing using
transgene-specific primers (Figure 4C). We found that, at day 19
post-transfection, both constructs were equally methylated at
HpaII sites with some evidence of spreading (average methylation
20.3% and 19.6% for long and short construct, respectively).
However, at day 57, the RIL short allele construct remained
methylated at the HpaII sites, and in addition, showed substantial
evidence of methylation spreading (average methylation 28.1%).
By contrast, the RIL long allele construct was found to have
demethylation, at HpaII sites, which coexisted with modest
methylation spreading on other sites and showed lower levels of
methylation overall (average methylation 11.7%). Thus, the short
allele construct was methylated 2.4-fold higher than the long allele
construct on day 57 (P,0.001 by Fisher exact test). Interestingly,
new methylation in the short construct did not seem to be
spreading to CpG sites directly adjacent to HpaII-methylated sites,
but was rather observed randomly between those sites, a
phenomenon that has been reported previously [10]. Further-
more, to more fully characterize methylation status of the
transgenes, we designed plasmid-specific pyrosequencing assays
and measured several time points (Figure 4D). In general, our
methylation and expression data agreed well. However, we must
point out that the degree of loss of expression observed for the
short alleles cannot be fully explained by methylation gains, thus
factors other than methylation (i.e. preceding chromatin changes)
might have contributed to the decline in luciferase activity, with
methylation following this. In summary, the stably integrated RIL
long allele construct is protected from methylation and time-
dependent silencing, consistent with several previous observations
that Sp1 sites confer protection against DNA methylation [11].
Discussion
Here we have identified a genetic variation in the promoter region
of RIL that results from a presumed insertion of 12 bp around
transcription start. This naturally occurring insertion results in a
significant 1.8-fold lower methylation of the gene in normal samples,
and a 2.1-fold to 3.1-fold lower methylation in cancer that we have
traced to the creation of a new Sp1/Sp3 binding site. This finding is
consistent with previous reports identifying Sp1 sites as regulatory
DNA elements protecting CpG islands from methylation during
embryogenesis [12]; [13] and can now be extended to hypermethyla-
tion in aging and cancer. This model is consistent with the concept
proposed by Turker and others [14], which suggests that methylation
is a non-random process that results in a misbalance between DNA
methylation-promoting events (e.g. abnormal spreading of methyla-
tion in cis from adjacent ‘‘methylation centers’’, repeat elements; and
methylation ‘‘seeding’’) and DNAmethylation preventing events (i.e.,
Sp1 elements in the promoters as well as other insulator sequences,
and proteins bound to those sequences; as well as demethylation).
Our study demonstrates that trans-acting factors can affect
hypermethylation in aging and cancer, and establish a new concept
in gene inactivation whereby genetic polymorphisms in protein
binding sites result in variable susceptibility to epigenetic silencing. A
relationship between genetic polymorphisms and aberrant methyla-
tion was recently described for MSH2 and was named heritable
germline epimutation [15]. A similar relationship has also been
described for MGMT [16]. In these cases, the exact mechanism of
such predispositions is unknown. It is attractive to think that these
heritable epimutations mechanistically represent polymorphisms that
influence DNA-binding proteins, as in the case of RIL. It would now
be of interest to determine how many genes hypermethylated in
cancer are affected by such promoter polymorphisms.
The mechanism of Sp1/Sp3 protection against silencing remains
unclear. Our studies of RIL expression both in vivo in EBV-
transformed cells (Figure 2) and in vitro (Figure 4A), using allele-
specific reporter gene assays showed no difference in expression levels
between the two alleles of RIL. Rather, our results with the in vitro
seeding model are generally consistent with the idea that it protects
against time-dependent silencing. However, the degree of methyla-
tion spreading observed in the short alleles cannot quantitatively
explain the observed prominent drop in transcription over time
(Figure 4B–D), and we suggest that the effects of the additional Sp1/
Sp3 site are to create local protection against a repressive chromatin
environment (e.g. histone based silencing) which, secondarily, leads to
the observed DNA methylation differences. There are also clear
limitations to short term in-vitro assays in modeling in-vivo situations.
The experiments described attempt to reproduce in a relatively short
period of time an in-vivo situation which evolves over decades of
human aging. Nevertheless, it provides an experimental validation of
the in-vivo situation, and shows that the short alleles are more prone
to time dependent silencing.
Our findings are in line with previous in-vitro studies of the
APRT gene that suggested that different Sp1 sites might have
different functions; some involved in regulation of gene expression,
whereas others in protection against DNA methylation [11]. In
support of this model, recent data pointed out that Sp1 may have
boundary activities and prevent heterochromatin spreading in
yeast, which lack Sp1 homologues: targeting of Sp1 to transgenes
in yeast cells unexpectedly revealed barrier activity, which was
independent of a transactivation domain [17]. It is tempting to
speculate that the Sp1/Sp3 site created by the polymorphism in
RIL plays such a role.
Identification of allelic variants of genes that have different
susceptibility to methylation in aging and cancer is an important
new link between human genetic variation and epigenetic
silencing. In this study, we propose a plausible mechanism
responsible for this unique biological phenomenon.
Materials and Methods
Cell Lines and Culture Conditions
HCT116, RKO and NIH3T3 cells were grown in high glucose
DMEM (Life Technologies, Gaithersburg, MD) plus 10% fetal
plasmid-specific primers. Note equal methylation levels and presence of initial ‘‘seeds’’ of HpaII methylation (arrowheads) on day 19 and increased
methylation spreading for the short allele construct at day 57. Percent methylation for each time point is indicated. (D) Pyrosequencing results for
allele-specific seeded constructs. The methylation status of the transfected allele-specific constructs was analyzed by pyrosequencing at indicated
time points, using plasmid-specific primers. One site was analyzed by the assay, which corresponds to CpG site# 9 in bisulfite sequencing figure. The
pyrosequencing results shown agree with expression and bisulfite sequencing data.
doi:10.1371/journal.pgen.1000162.g004
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bovine serum (FBS; Intergen, Purchase, NY); OVCAR-5, PC3,MB-
231 and the EBV-transformed cells were grown in RPMI 1640
media plus 10% FBS. All cells were grown in plastic tissue culture
plates in a humidified atmosphere containing 5% CO2 at 37uC.
Human Samples
Samples of primary colon cancers and primary leukemias were
obtained from established tissue banks at M. D. Anderson Cancer
Center and Johns Hopkins University. Of 44 primary colon cancer
samples, 10 were stage II, 12 stage II, 7 stage IV, and 15 were of
unknown stage. EBV-transformed lymphocyte cell lines estab-
lished from normal Caucasian individuals were obtained from
Baylor College of Medicine. All samples were collected from
consenting patients according to institutional guidelines.
DNA, RNA extraction, and cDNA Synthesis
DNA was extracted by using conventional phenol-chloroform
method. Total cellular RNA was extracted with TriZOL
(Invitrogen, Carlsbad, CA) according to the manufacturer protocol
and resuspended in DEPC-treated water. Reverse transcription
reactions were performed using MMLV-RT (Roche, Indianapolis,
IN) on 2 mg of total RNA per reaction according to the
manufacturer’s protocol.
Genotyping
Genotyping to determine RIL allele status was performed by
genomic PCR using del7 (TCCAGGCGCACAGGGAGC) and
del8 (GCCTGAGCCGGACTCTGAGGA) primers. PCR prod-
ucts were separated on 6% polyacrylamide gel and were classified
as short, long, or heterozygous, depending on the size and number
of bands. Several cases were verified by direct sequencing.
Bisulfite Modification of DNA
Bisulfite induces deamination of unmethylated cytosines,
converting unmethylated CpG sites to UpG without modifying
methylated sites. Bisulfite treatment of genomic DNA was
performed as described [18]. DNA was extracted using standard
phenol-chloroform method. After extraction, 2 mg of DNA were
used for bisulfite treatment. DNA was denatured in 0.2 N NaOH
at 37uC for 10 min and incubated with 3 M sodium bisulfite at
50uC for 16 h. Bisulfite-converted DNA was purified using the
Wizard cleanup system (Promega, Madison, WI) and desulfonated
with 0.3 N NaOH at 25uC for 5 min. DNA was then precipitated
with ammonium acetate and ethanol, washed with 70% ethanol,
dried and resuspended in H2O.
COBRA Analysis and Bisulfite Sequencing
PCR reactions were carried in 50-ml reactions using the COBRA
primers (forward, GTTTATTAGGYGGAAGTTTTAGG and
reverse, AACCAATCCAAACRCACAA) are complementary to
the RIL antisense strand. In each reaction, 2 ml of bisulfite-treated
DNA were used, as well as 1.25 mM deoxynucleotide triphosphate,
67 mM Tris-HCl, pH=8.8, 16 mM ammonium sulfate, 10 mM b-
mercaptoethanol, 0.1 mg/ml bovine serum albumin, 10 pmol of
primers and 1 unit of Taq polymerase. All PCR reactions were
performed using a hot start at 95uC for 5 min. After amplification
PCR products were digested with the HpyCH4IV restriction
enzyme (New England Biolabs, Ipswitch, MA), which digests alleles
that were methylated prior to bisulfite treatment. The digested DNA
was separated in nondenaturing polyacrylamide gels and stained
with ethidium bromide. The proportion of methylated versus
unmethylated product (digested versus undigested) was quantitated
by densitometric analysis, performed using a Bio-Rad Geldoc 2000
digital analyzer equipped with the Quantity One version 4.0.3
software. In case of bisulfite sequencing, restriction enzyme digestion
step was omitted, PCR products were directly cloned into a TOPO-
TA vector (Invitrogen, Carlsbad, CA) and individual clones were
sequenced.
Pyrosequencing
To study methylation in normal colon, primary cancer samples
and in 3T3 cells transfected with HpaII-seeded constructs, we used
the pyrosequencing method [19]. For PCR, we used 2 mL bisulfite
treated DNA, 1.25 mM deoxynucleotide triphosphate, 1 unit of
Taq polymerase and the PCR buffer mentioned above, 10 pmol
forward primer, 1 pmol reverse-universal primer, and 9 pmol
universal biotinylated primer (assays E, F, G). In assay A, we used
1 pmol forward-universal primer, 10 pmol reverse primer and
9 pmol universal biotinylated primer. In assay B, the reverse
primer was directly biotinylated. In plasmid-specific assays, we
used a two-step PCR approach using nested primers, and in the
second step, we used 10 pmol forward primer, 1 pmol reverse-
universal primer, 1 pmol reverse primer and 9 pmol universal
biotinylated primer. All primer sequences and conditions are
shown in Supplementary Table S1. The final biotin-labeled PCR
product was captured by Streptavidin Sepharose HP (Amersham
Biosciences, Sweden). PCR products bound on the bead were
purified and made single stranded using a Pyrosequencing
Vacuum Prep Tool (Biotage, Sweden). The sequencing primers
(0.3 mmol/L; Supplementary Table S1) were annealed to the
single-stranded PCR product, and pyrosequencing was done using
the PSQ HS 96 Pyrosequencing System (Biotage, Sweden).
Quantification of cytosine methylation was done using the
provided software (PSQ HS96A 1.2).
Nuclear Cell Extracts
Nuclear extracts were prepared with the NE-PER nuclear
extraction reagents (Pierce, Rockford, IL), according to manufac-
turer’s instructions. Briefly, cells were lysed in hypotonic CER
buffer with added protease inhibitors and the cytoplasmic fraction
was separated by centrifugation. The nuclear pellet was resus-
pended in hypertonic NER buffer with added protease inhibitors
and incubated on ice for 409, vortexed every 109. For nuclear
extracts, the soluble proteins in the lysate were separated by
centrifugation. The protein content was quantified using the Bio-
Rad protein assay.
Electrophoretic Mobility Shift Assay
All EMSA probes were generated by annealing synthetic
complementary oligonucleotides (Invitrogen) corresponding to
the deletion/insertion region of the RIL promoter, sequences
are shown in Figure 4A. 32P-end-labeled oligonucleotides
(100,000 cpm) were incubated for 30 min on ice with 5–10 mg
of nuclear extract or, alternatively, with 200 ng of recombinant
human Sp1 (Promega) in 15 ml of binding buffer containing
10 mM Tris-HCl, pH 7.5, 0.5 mM EDTA, 0.5 mM dithiothre-
itol, 4% glycerol, 1 mM MgCl2, 50 mM NaCl, and 1 mg of
poly(dI-dC). The binding reaction was incubated on ice for
30 min. Competition reactions were performed with a 20-fold
molar excess of unlabeled double-stranded competitor DNA. For
supershift analysis, the nuclear extracts were incubated with
polyclonal anti-human Sp1, Sp3, Egr-1 and AP-2 antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h following the
binding reaction with labeled probe. The DNA-protein complexes
were separated on a 5% native polyacrylamide gel in 0.56TBE
buffer for 14 h at +4uC at 90 V.
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Construction and Transfection of RIL Allele Specific
Luciferase Reporter Plasmids
DNA from human colon cancer cells HCT116 and RKO was
extracted as previously described, using phenol chloroform methods.
The more 39 located transcription start site (Figure 1A) was arbitrarily
chosen as +1. The 236-bp genomic fragment from HCT116 cells
(homozygous long) and the 224-bp genomic fragment from RKO
cells (homozygous short) spanning from 2217 to +19 (construct A)
were generated by PCR from genomic DNA using RIL-LUC1
(CGGAGCTCTCTCTGAGAGCTGAGTGGGG) and RIL-
LUC2 (GCAAGCTTCTGAGCCGGACTCTGAGG) primers.
The 607-bp genomic fragment from HCT116 cells and the 595-bp
genomic fragment from RKO cells spanning from 2588 to +19
(construct B) were generated by PCR from genomic DNA using RIL-
LUC3 and RIL-LUC2 primers. Both RIL-LUC1 and RIL-LUC3
(GGGAGCTCCCTTACTGGCCTCCACAAAC) primers con-
tained SacI restriction enzyme sites, whereas RIL-LUC2 primer
contained HindIII restriction site. The genomic fragments from
HCT116 cells (homozygous long) and from RKO cells (homozygous
short) spanning from 2588 to +516 (construct C) were generated by
PCR from genomic DNA using RIL-LUC4 (GTGCTAGCCCT-
TACTGGCCTCCACAAAC) and RIL-LUC5 (CCAAGCTTG-
GACCTGCGAGCAGACAAGCCTCATTTTGCCCCAGATC-
TTC) primers. In construct C, the reverse primer contained addi-
tional intronic sequence to assure correct splicing of the exon 1. The
PCR products were digested with NheI and HindIII enzymes (NEB)
and subcloned in the promoterless pGL3 basic vector (Promega)
and, generating the allele-specific constructs A (236/224-bp), B
(607/595-bp) and C (1104/1092-bp). The constructs were con-
firmed by DNA sequencing. Plasmids were transfected using Lipo-
fectamine2000 (Invitrogen), according to manufacturer’s protocol.
Transient Transfections and Luciferase Assay
The cells were grown in 6-well plates to 60% confluence for at
least 18 h and then were transiently transfected using Fugene6
reagent (Roche, Indianapolis, IN) with 1 mg of a firefly luciferase
reporter gene and 50 ng of the Renilla luciferase reporter gene,
driven by the thymidine kinase promoter (Promega). Cotransfec-
tion was performed by adding 1 mg of expression constructs to the
DNA solutions. Luciferase activity was determined using the dual
luciferase reporter assay system (Promega) in a microplate
Monolight 3010 luminometer (BD Biosciences, San Diego, CA)
according to the manufacturer’s instructions. Normalization of
transfection efficiency was based on cotransfected thymidine
kinase Renilla luciferase activities.
HpaII Methylation Seeding, Stable Transfections, Bisulfite
PCR, and Pyrosequencing
RIL allele-specific constructs (construct B, ,0.6 KB) were
methylated using HpaII methylase (NEB) according to manufac-
turer’s protocol. Methylation was confirmed by resistance to
restriction to HpaII enzyme (Figure S3). For stable transfections,
allele-specific luciferase constructs were co-transfected with
pcDNA3.1 neomycin-containing vector in 20:1 ratio into 3T3
cells using Lipofectamine 2000 (Invitrogen). Methylation analysis
of transfected constructs was done by amplification of bisulfite
treated DNA, using plasmid-specific primers (F: GAGAGTT-
GAGTGGGGGTGT, R: TTCCATAATAACTTTACCAA-
CAATACC) followed by bisulfite sequencing of single clones.
For pyrosequencing, these primers were used for the 1st step PCR,
followed by second step with nested primers (Supplementary
Table S1). One site was analyzed by the assay, which corresponds
to CpG site # 9 in bisulfite sequencing (Figure 4C).
Real-Time PCR
Q-PCR was used to quantify RIL mRNA in total RNA isolated
from EBV-transformed lymphoblastoid cell lines and reverse
transcribed into cDNA, and also to estimate relative plasmid copy
numbers in the genomic DNA isolated from pooled transfected
NIH3T3 cells. We used TaqMan Universal PCR Master Mix and
ABI Prism 7000 Sequence Detection System (Applied Biosystems,
Foster City, CA). The primers and TaqMan probes were designed by
using Primer Express software (Applied Biosystems), except for RIL
expression assay which was custom-designed and purchased from
Applied Biosystems (cat. No. Hs00184792_m1). All probes were
labeled with the 6-carboxyfluorescein fluorophore (6-FAM) and a
nonfluorescent MGB quencher. To normalize RIL expression,
GAPDH was used as reference standards; to estimate the relative
plasmid copy number per cell, murine beta-globin was used as
endogenous reference. Primer and probe sequences used in the
experiments were as follows: (1) RIL assay, custom-designed and
purchased from Applied Biosystems, cat. No. Hs00184792_m1; (2)
GAPDH assay, gapdh-284F, 59-ATGGAAATCCCATCACCATC-
TT-39; gapdh-340R, 59-CGCCCCACTTGATTTTGG-39; gapdh-
307T (MGB probe, FAM fluorophore labeled), 5-CGCAGTTGGG-
CACTT-3; (3) Luciferase assay, luc-161F, 59-CACATATC-
GAGGTGGACATC-39; luc-220R, 59- GCCAACCGAACGGA-
CATTT-39; luc-184T (MGB probe, FAM fluorophore labeled),
5-CTTACGCTGAGTACTTC-3; (4) Murine beta-globin assay,
Mu-bglo-239F, 59- AGGCCCATGGCAAGAAAGT-39, Mu-bglo-
306R, 59-GCCCTTGAGGCTGTCCAA-39, Mu-bglo-259T (MGB
probe, FAM fluorophore labeled), 5-ATAACTGCCTTTAAC-
GATG-3. All FAM probes were custom synthesized by Applied
Biosystems. The primers were used at 900 nM and the probes at
100 nM concentrations. We used the RNA or DNA amount giving
the linear range of response, typically CT range of 20–30
amplification cycles. We amplified each gene in separate reactions
in triplicates, using a protocol recommended by manufacturer. PCR
without reverse transcriptase was performed for each sample to
control for the possible interference from gDNA contamination. The
threshold amplification cycles (CT) at the normalized reporter signal
minus the baseline signal level of 0.2 for RIL, GAPDH, Luciferase
and murine beta-globin were determined and their differences
deltaCT(GAPDH-RIL) and deltaCT(murine beta globin-Luciferase)
were calculated.
Statistics
Statistical differences of bisulfite sequencing data were calculat-
ed using Fisher exact test. To analyze methylation levels across the
CpG island, we calculated average6standard error of the mean
for each region studied, and performed T-test using Microsoft
Excel. To estimate correlation between average methylation
density (regions A–F) and age for each region in normal colon
samples, non-parametric two-tail Spearman test (95% confidence
interval) was used (Graphpad Prizm 4 software). All EMSA
experiments were done in triplicates and yielded identical results.
Luciferase assays on cells were performed three separate times,
and the results were expressed as average6standard error of the
mean calculated using Microsoft Excel.
Supporting Information
Figure S1 Differential methylation of RIL alleles in homozygous
and heterozygous tumors revealed by COBRA assay. Here, a RIL
COBRA gel image for representative colon cancer and paired
normal samples, as well as ML-1 cell line is shown. Allele status of
samples is indicated on the top of the gel. In the middle of the gel,
the upper arrow indicates an allele-specific band, which is seen
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only if the long allele undergoes methylation, whereas the lower
arrow points to the allele-specific band that is seen if the short
allele is methylated. In the bottom of the gel, an allele non-specific
band is seen, which is always present if RIL is methylated,
regardless of allele status. After digestion of the COBRA products
obtained from several homozygous and heterozygous tumors, we
observed that among the 2 middle allele-specific bands, the
predominant one is the lower band, which represents methylated
short allele molecules. Note methylation of only the S allele in
heterozygous cases C110 and C140. These findings led us to a
suspicion that the short allele is more methylated than the long.
Found at: doi:10.1371/journal.pgen.1000162.s001 (0.27 MB TIF)
Figure S2 Mixing study for pyrosequencing assay A. Normal
blood (unmethylated) DNA was mixed with methylated DNA
(RKO) at known ratios and subjected to bisulfite treatment. Then,
pyrosequencing assay A (Figure 1A) was tested for bias of
estimating methylation by studying mixed RKO, which has near
100% methylation as determined previously by COBRA, bisulfite
sequencing, and pyrosequencing assays. The graph shows
pyrosequencing measurement values determined for bisulfite-
treated DNA of mixed RKO and normal blood in the ratio shown
on the X-axis. Measured values are plotted alongside with
expected methylation values, which are in fact very similar. Thus,
we conclude that there is no bias in amplifying unmethylated vs.
methylated DNA with the assay.
Found at: doi:10.1371/journal.pgen.1000162.s002 (0.04 MB TIF)
Figure S3 The HpaII seeding of allele-specific construct B was
done by HpaII methylase treatment and the plasmid methylation
status prior to transfections was validated first by HpaII restriction
enzyme (methylation sensitive) digestion. The gel image shows that
while unmethylated allele-specific plasmids (lane 2, RIL-long and
lane 4, RIL-short constructs) were digested into low size fragments,
seeded plasmid were resistant to digestion (lane 1, RIL-long and
lane 3, RIL-short methylation seeded constructs). lM1, HindIII
marker and M2, 100-bp marker.
Found at: doi:10.1371/journal.pgen.1000162.s003 (0.70 MB TIF)
Figure S4 Expression of stably transfected HpaII-seeded
constructs in an independent second experiment. Long and short
RIL allele-specific constructs (construct B, ,0.6 KB) were seeded
with HpaII methylase, stably cotransfected with pcDNA3.1 into
NIH3T3 cells, selected in neomycin and pooled clones monitored
for the indicated time period. Notice initial equal levels of
expression (Day 18), followed by increase or maintenance of the
long allele construct expression and in contrast, declining
expression of the short allele construct.
Found at: doi:10.1371/journal.pgen.1000162.s004 (0.06 MB TIF)
Table S1 Primer Sequences for the Genes Studied, PCR
Conditions, and Assay Locations.
Found at: doi:10.1371/journal.pgen.1000162.s005 (0.02 MB PDF)
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